GH Research (NASDAQ:GHRS – Get Free Report) and Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.
Profitability
This table compares GH Research and Cadrenal Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GH Research | N/A | -16.39% | -15.83% |
| Cadrenal Therapeutics | N/A | -93.70% | -82.23% |
Valuation & Earnings
This table compares GH Research and Cadrenal Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GH Research | N/A | N/A | -$35.59 million | ($0.62) | -11.27 |
| Cadrenal Therapeutics | N/A | N/A | -$8.36 million | ($0.31) | -32.84 |
Risk and Volatility
GH Research has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500.
Institutional and Insider Ownership
56.9% of GH Research shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 41.6% of GH Research shares are owned by company insiders. Comparatively, 48.6% of Cadrenal Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of recent recommendations for GH Research and Cadrenal Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GH Research | 0 | 0 | 3 | 0 | 3.00 |
| Cadrenal Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
GH Research presently has a consensus price target of $36.67, suggesting a potential upside of 424.56%. Cadrenal Therapeutics has a consensus price target of $0.23, suggesting a potential downside of 97.71%. Given GH Research’s higher probable upside, equities research analysts clearly believe GH Research is more favorable than Cadrenal Therapeutics.
Summary
GH Research beats Cadrenal Therapeutics on 6 of the 10 factors compared between the two stocks.
About GH Research
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
About Cadrenal Therapeutics
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.
